Memantine Hydrochloride And Donepezil Hydrochloride Capsule, Extended Release
NDC Package 69680-183-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Memantine Hydrochloride And Donepezil Hydrochloride capsules is memantine and donepezil hydrochlorides extended-release capsules is indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. This formulation utilizes a capsule, extended release delivery system. Marketed by Vitruvias Therapeutics, Inc., this product is identified by NDC 69680-183 and is authorized under FDA application ANDA216901.

Identification & Billing

NDC Package Code
69680-183-30
Package Description
30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
69680-183
11-Digit Billing Format
69680018330
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 1599803 - donepezil HCl 10 MG / memantine HCl 28 MG 24HR Extended Release Oral Capsule
  • RxCUI: 1599803 - 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 28 MG Extended Release Oral Capsule
  • RxCUI: 1599803 - donepezil hydrochloride 10 MG / memantine hydrochloride 28 MG 24 HR Extended Release Oral Capsule
  • RxCUI: 1599805 - donepezil HCl 10 MG / memantine HCl 14 MG 24HR Extended Release Oral Capsule
  • RxCUI: 1599805 - 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Memantine Hydrochloride And Donepezil Hydrochloride
Non-Proprietary Name
Memantine Hydrochloride And Donepezil Hydrochloride
Substance Name
Donepezil Hydrochloride; Memantine Hydrochloride
Dosage Form
Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Memantine and donepezil hydrochlorides extended-release capsules is indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily.

Regulatory & Marketing

Labeler Name
Vitruvias Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA216901
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-16-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69680-183-30 identifies a specific commercial package of 30 capsule, extended release in 1 bottle of Memantine Hydrochloride And Donepezil Hydrochloride, a human prescription drug labeled by Vitruvias Therapeutics, Inc.. This capsule, extended release is formulated for oral use and contains donepezil hydrochloride; memantine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vitruvias Therapeutics, Inc. on July 16, 2025. The current certification is valid through December 31, 2026.

How is this Vitruvias Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69680018330. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69680-183-30
11-Digit CMS (5-4-2)
69680-0183-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.